Prohost BiotechResearch Platform

Home Articles Prohost LettersStories about research, clinical trials results and an FDA ruling

Prohost Letters

Premium

Stories about research, clinical trials results and an FDA ruling

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its...

P

Prohost Biotech

July 9, 2018

1 min read

21

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

AbbVie Inc (ABBV)

Acceleron Pharma (XLRN)

Alkermes (ALKS)

Beam Therapeutics Inc Celgene (CELG)

Cellectis (CLLS)

CRISPR Therapeutics (CRSP)

Editas Medicine Inc (EDIT)

Enanta Pharmaceuticals (ENTA)

Exelixis (EXEL)

Prohost Portfolio

Sangamo Therapeutics Inc (SGMO)

Comments (0)

Please sign in to join the discussion

Related Articles

Prohost Letters

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. T...

Prohost Biotech

Aug 21, 2024

Prohost Letters

Prohost Letter #460 ~ Treating IgA Nephropathy

Prohost Letter #460 Treating IgA Nephropathy Immunoglobulin A ( IgA ), the antibody of the immune system known to fight infections, can itself cause two important diseases. It can attack the body caus...

Prohost Biotech

Jun 1, 2024

Prohost Letters

Prohost Letter #459 ~ NAFLD & NASH

Prohost Letter #459 ~ NAFLD & NASH NAFLD is Non-Alcoholic Fatty Liver Disease, and NASH is Non-Alcoholic Steatohepatitis. We will start with NAFLD. NAFLD The Non-Alcoholic Fatty Liver Disease is cau...

Prohost Biotech

Mar 3, 2024